COMP <GO>
RYTM vs LGND // EV/EBITDA & P/E VALUATION
Rhythm Pharmaceuticals Inc. (NASDAQ) VS. Ligand Pharmaceuticals Incorporated (NASDAQ) • 15-METRIC TALLY: RYTM 2
— LGND 9
■ METRIC PARITY
LAST: $93.44 (+0.94%) • MKT CAP: $6.37B
valuation
—
LAST: $307.02 (-4.87%) • MKT CAP: $6.43B
valuation
95.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RYTM VS. LGND)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RYTM | LGND | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -29.60% | 3.00% | -32.60 | LGND | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 95.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.82% | 0.77% | -2.59 | LGND | /fcf-yield <GO> |
| Operating Margin | -60.00% | 15.30% | -75.30 | LGND | /operating-margins <GO> |
| Net Profit Margin | -0.10% | 46.40% | -46.50 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 45.80% | 60.40% | -14.60 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 8.40 | +5.93 | RYTM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | LGND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 61.9 | -11.90 | LGND | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.07 | -0.11 | LGND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 42.7x | -9.70 | RYTM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.37B | $6.43B | -$60.6M | LGND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RYTM REV | LGND REV | RYTM GROSS % | LGND GROSS % | RYTM FCF | LGND FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $189.8M | $268.1M | 89.7% | — | -$116.6M | $48.9M |
| FY 2024 | $130.1M | $167.1M | 89.7% | — | -$113.9M | $95.2M |
| FY 2023 | $77.4M | $131.3M | — | — | -$139.6M | $43.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RYTM // BETA 0.96
LGND // BETA 1.07